Development of GLP-1MK-801 To safely harness the weight-lowering properties of NMDA receptor antagonism, we developed a targeting approach based on the hypothesis that conjugation of MK-801 to a GLP-1 analogue through a chemically cleavable disulfide linker would enhance the therapeutic potential of NMDA receptor antagonism in appetite-regulating brain regions enriched for GLP-1 receptors, while mitigating the adverse effects related to the non-restricted actions of MK-801
Gasdermin E (GSDME, also called DFNA5) was recently identified as another pyroptotic executioner and suppresses tumor growth by activating anti-tumor immunity (168)
Hwang WL, Jagadeesh KA, Guo JA, Hoffman HI, Yadollahpour P, Reeves JW, Mohan R , Drokhlyansky E, Van Wittenberghe N, Ashenberg O, Farhi SL, Schapiro D, Divakar P, Miller E, Zollinger DR, Eng G, Schenkel JM, Su J, Shiau C, Yu P, Freed-Pastor WA, Abbondanza D, Mehta A, Gould J, Lambden C, Porter CBM, Tsankov A, Dionne D, Waldman J, Cuoco MS, Nguyen L, Delorey T, Phillips D, Barth JL, Kem M, Rodrigues C, Ciprani D, Roldan J, Zelga P, Jorgji V, Chen JH, Ely Z, Zhao D, Fuhrman K, Fropf R, Beechem JM, Loeffler JS, Ryan DP, Weekes CD, Ferrone CR, Qadan M, Aryee MJ, Jain RK, Neuberg DS, Wo JY, Hong TS, Xavier R, Aguirre AJ, Rozenblatt-Rosen O, Mino-Kenudson M, Castillo CF, Liss AS, Ting DT, Jacks T, Regev A
The effects of chronic stress on health: new insights into the molecular mechanisms of brain-body communication
